what is ipamorelin?

Ipamorelin did not appear from nowhere. It is the fourth generation of a research program Cyril Bowers started at Tulane in the late 1970s, refined by Novo Nordisk's medicinal-chemistry team in Maaloev, Denmark, in the mid-1990s. The thread connecting all four molecules is the same receptor: GHS-R1a, the ghrelin receptor on pituitary somatotrophs.

Each generation traded raw potency for cleaner selectivity. GHRP-6 released GH but also drove hunger, cortisol, and prolactin. GHRP-2 and hexarelin trimmed some of that but kept the HPA-axis noise. Ipamorelin removed the cortisol, prolactin, and ACTH co-release entirely -- the defining claim of the Raun 1998 paper that has held up across two decades of literature.

Ghrelin itself is the endogenous ligand. It was identified by Kojima and Kangawa in 1999 -- a year after ipamorelin was already published. The receptor was deorphanized in 1996 by Howard et al. at Merck. The synthetic GHRPs reached the target before anyone knew what the target's natural ligand was.

The next nine units take what you just read and go deeper. Unit 2 covers the endogenous GH axis -- somatotrophs, the pulsatile rhythm, slow-wave-sleep biology. Unit 3 walks the pentapeptide residue-by-residue. Unit 4 dissects the selectivity claim. Unit 5 covers the CJC-1295 stack and the DAC-vs-no-DAC debate. Unit 6 grades the trial evidence honestly -- including the negative Beck 2014 RCT. Units 7-9 cover applications, safety, and dosing. Unit 10 covers the regulatory arc through the October 2024 PCAC vote.

By the end you will be able to read any peptide-forum thread on ipamorelin and immediately tell which claims rest on mechanism, which rest on rodent data, and which are pure marketing. That's the goal -- not to recommend ipamorelin or push you away from it, but to make you the most calibrated person in the room when the topic comes up.